Fujitsu Japan Embarks on Joint Research for COVID-19 Therapies Using World’s Fastest Supercomputer with Researchers of RCAST, The University of Tokyo
TOKYO, Jun 22, 2021 - (JCN Newswire via SEAPRWire.com) - Fujitsu Japan Limited today announced that it will initiate a new research project with a research team led by Takefumi Yamashita, Project Associate Professor of Research Center for Advanced Science and Technology (RCAST) , the University of Tokyo utilizing the world's fastest supercomputer, Fugaku, which was jointly developed by RIKEN and Fujitsu. The research will leverage Fugaku to identify small molecule inhibitory compounds that can be used as potential drugs in treatments for COVID-19 as well as clarifying the molecular mechanism by which COVID-19 infections are inhibited, leading to the eventual development of small molecule therapeutic drugs. Full scale research begins on June 22nd, 2021 and will continue until March of 2022.Fig.1 Docking simulation of viral protein and inhibitory compoundFig. 2 Molecular Dynamics Simulations of Viral Proteins and Inhibitory CompoundsFig. 3 Property prediction of mutant strainsIn their joint research, Fujitsu and RCAST will leverage IT drug discovery technology with a focus on inhibitory compound creation technology and molecular simulation technology that precisely represents the sta...
